The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
An Industry Perspective on the Monitoring of Subvisible Particles as a Quality Attribute for Protein Therapeutics
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gee, G. W., & Bauder, J. W. (1986) · SSSA Book Series · doi:10.2136/sssabookser5.1.2ed.c15 · Cited by 8,807
Effects of protein aggregates: An immunologic perspective
Rosenberg, A. S. (2006) · The AAPS Journal · doi:10.1208/aapsj080359 · Cited by 1,355
Protein aggregation: Pathways, induction factors and analysis
Mahler, H.-C., Friess, W., Grauschopf, U., & Kiese, S. (2009) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21566 · Cited by 901
Self-citationImmunogenicity of engineered antibodies
Hwang, W. Y. K., & Foote, J. (2005) · Methods · doi:10.1016/j.ymeth.2005.01.001 · Cited by 630
Carpenter, J. F., Randolph, T. W., Jiskoot, W., Crommelin, D. J. A., Russell Middaugh, C., Winter, G., Fan, Y.-X., Kirshner, S., Verthelyi, D., Kozlowski, S., et al. (2009) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21530 · Cited by 595
Shaken, Not Stirred: Mechanical Stress Testing of an IgG1 Antibody
Kiese, S., Papppenberger, A., Friess, W., & Mahler, H.-C. (2008) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21328 · Cited by 397
Self-citationFactors influencing the immunogenicity of therapeutic proteins
Schellekens, H. (2005) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfh1092 · Cited by 332
Braun, A., Kwee, L., Labow, M. A., & Alsenz, J. (1997) · Pharmaceutical Research · doi:10.1023/a:1012193326789 · Cited by 298
Is any measurement method optimal for all aggregate sizes and types?
Philo, J. S. (2006) · The AAPS Journal · doi:10.1208/aapsj080365 · Cited by 245
A critical review of methods for size characterization of non-particulate protein aggregates
Philo, J. (2009) · Current Pharmaceutical Biotechnology · doi:10.2174/138920109788488815 · Cited by 196
Hermeling, S., Schellekens, H., Maas, C., Gebbink, M. F. B. G., Crommelin, D. J. A., & Jiskoot, W. (2006) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20599 · Cited by 185
Immunogenicity of aggregates of recombinant human growth hormone in mouse models
Fradkin, A. H., Carpenter, J. F., & Randolph, T. W. (2009) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21834 · Cited by 170
A Critical Review of Analytical Methods for Subvisible and Visible Particles
Narhi, L. O., Jiang, Y., Cao, S., Benedek, K., & Shnek, D. (2009) · Current Pharmaceutical Biotechnology · doi:10.2174/138920109788488905 · Cited by 152
Self-citationBugelski, P. J., & Treacy, G. (2004) · PubMed · Cited by 130
Quantitation of protein particles in parenteral solutions using micro-flow imaging
Huang, C.-T., Sharma, D., Oma, P., & Krishnamurthy, R. (2008) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21575 · Cited by 129
How to predict and prevent the immunogenicity of therapeutic proteins
Schellekens, H. (2008) · Biotechnology annual review · doi:10.1016/s1387-2656(08)00007-0 · Cited by 100
How to systematically evaluate immunogenicity of therapeutic proteins – regulatory considerations
Jahn, E., & Schneider, C. K. (2009) · New Biotechnology · doi:10.1016/j.nbt.2009.03.012 · Cited by 93
Influence of aggregation on immunogenicity of recombinant human Factor VIII in hemophilia A mice
Purohit, V. S., Middaugh, C. R., & Balasubramanian, S. V. (2005) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20529 · Cited by 92
Development of a Transgenic Mouse Model Immune Tolerant for Human Interferon Beta
Hermeling, S., Jiskoot, W., Crommelin, D. J. A., Bornæs, C., & Schellekens, H. (2005) · Pharmaceutical Research · doi:10.1007/s11095-005-4578-z · Cited by 72
Separation and Characterization of Protein Aggregates and Particles by Field Flow Fractionation
Cao, S., Pollastrini, J., & Jiang, Y. (2009) · Current Pharmaceutical Biotechnology · doi:10.2174/138920109788488978 · Cited by 58
Mahler, H., Fischer, S., Randolph, T. W., & Carpenter, J. F. (2010) · Wiley eBooks · doi:10.1002/9780470769829.ch7 · Cited by 35
Self-citationWhite, P. J., Anastasopoulos, F., Church, J. E., Kuo, C.-Y., Boyd, B. J., Hickey, P., Tu, L. S., Burns, P., Lew, A. M., Heath, W. R., et al. (2008) · Vaccine · doi:10.1016/j.vaccine.2008.09.087 · Cited by 13
Cited by
Microneedle technologies for (trans)dermal drug and vaccine delivery
van der Maaden, K., Jiskoot, W., & Bouwstra, J. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.01.042 · Cited by 651
Analytical tools for characterizing biopharmaceuticals and the implications for biosimilars
Berkowitz, S. A., Engen, J. R., Mazzeo, J. R., & Jones, G. B. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3746 · Cited by 529
Immunogenicity of Therapeutic Protein Aggregates
Moussa, E. M., Panchal, J. P., Moorthy, B. S., Blum, J. S., Joubert, M. K., Narhi, L. O., & Topp, E. M. (2016) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2015.11.002 · Cited by 529
Self-citationTherapeutic protein aggregation: mechanisms, design, and control
Roberts, C. J. (2014) · Trends in Biotechnology · doi:10.1016/j.tibtech.2014.05.005 · Cited by 455
Strategies for the assessment of protein aggregates in pharmaceutical biotech product development
den Engelsman, J., Garidel, P., Smulders, R., Koll, H., Smith, B., Bassarab, S., Seidl, A., Hainzl, O., & Jiskoot, W. (2011) · Pharmaceutical Research · doi:10.1007/s11095-010-0297-1 · Cited by 348
Metadata
- Authors
- Singh, S. K., Afonina, N., Awwad, M., Bechtold-Peters, K., Blue, J. T., Chou, D., Cromwell, M., Krause, H.-J., Mahler, H.-C., Meyer, B. K., Narhi, L., Nesta, D. P., & Spitznagel, T.
- Venue
- Journal of Pharmaceutical Sciences
- Publisher
- Elsevier BV
- Published
- 2010-08
- Volume
- 99
- Issue
- 8
- Pages
- 3302-3321
- ISSN
- 0022-3549 (ISSN-L)
- OpenAlex
- W2122748934
- Cited by
- 334
- References
- 22
- FWCI
- 10.16
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.